Eli Lilly & Co.'s Inc.'s stock soared 13% in premarket trade Thursday, after the drug maker reported positive results from a late-stage trial of an oral GLP-1 treatment for Type 2 diabetes.
The company $(LLY)$ said orforglipron showed statistically significant results and a safety profile that was consistent with injectable GLP-1 medicines in the Phase 3 trial. The once-daily treatment reduced weight by an average of 16 lbs at the highest dose in a secondary endpoint.
The drug is the first oral small-molecule GLP-receptor agonist to successfully complete a Phase 3 trial, said Lilly in a statement.
"We are pleased to see that our latest incretin medicine meets our expectations for safety and tolerability, glucose control and weight loss, and we look forward to additional data readouts later this year," said Lilly CEO David A. Ricks in prepared remarks.
(This is a breaking news story. Check back for updates)
-Ciara Linnane
For more from MarketWatch: http://www.marketwatch.com/newsviewer
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
April 17, 2025 07:15 ET (11:15 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。